There is a strong association between serum antibody responses to toxin A and protection against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very-high-level responses to anti-toxin A immunoglobulin G (IgG) in the sera of healthy volunteers. After vaccination, the concentrations of anti-toxin A IgG in the sera of all 30 recipients exceeded the concentrations that were associated with protection in previous clinical studies. Furthermore, the median concentration of serum anti-toxin A IgG in the test group was 50-fold higher than the previous threshold. These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC148861 | PMC |
| http://dx.doi.org/10.1128/IAI.71.3.1608-1610.2003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heterogeneity of Clostridioides difficile asymptomatic colonization prevalence: a systematic review and meta-analysis.
Gut Pathog
January 2025
Francis I Proctor Foundation, University of California San Francisco, 490 Illinois St, San Francisco, CA, 94158, USA.
Background: Asymptomatic carriers significantly influence the transmission dynamics of C. difficile. This study aimed to assess the prevalence of toxigenic C.
View Article and Find Full Text PDFProspective analysis of biomarkers associated with successful faecal microbiota transplantation in recurrent Clostridioides difficile Infection.
Clin Microbiol Infect
January 2025
Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain. Electronic address:
Objectives: Faecal microbiota transplantation (FMT) is an established treatment for recurrent Clostridioides difficile infection (R-CDI). This study aimed to identify calprotectin and microbiome characteristics as potential biomarkers of FMT success.
Methods: We conducted a prospective study of patients who underwent oral FMT (single dose of 4-5 capsules) for R-CDI (January 2018 to December 2022).
Impact of Hepatoblastoma on Infectious Complications Following Pediatric Liver Transplantation.
Pediatr Transplant
February 2025
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
Background: Liver transplantation is the standard therapy for end-stage liver disease in pediatric patients with biliary atresia (BA), congenital and metabolic conditions, and for an unresectable malignant tumor like hepatoblastoma (HB). BA is the leading indication for pediatric liver transplantation, while HB is the most common childhood liver cancer. Despite improved outcomes through advanced surgical techniques and novel immunosuppression, pediatric liver transplantation (pLT) is complicated by post-transplant infections.
View Article and Find Full Text PDFUnlabelled: infections cause over 12,000 deaths and an estimated one billion dollars in healthcare costs annually in the United States. The cell membrane is an essential structure that is important for protection from the extracellular environment, signal transduction, and transport of nutrients. The polar membrane lipids of are ∼50% glycolipids, a higher percentage than most other organisms.
View Article and Find Full Text PDFImpact of adjunct bezlotoxumab for preventing infection recurrence in patients post - hematopoietic stem cell transplantation.
J Oncol Pharm Pract
January 2025
Department of Pharmacy, SSM Health Saint Louis University Hospital, Saint Louis, MO, USA.
Background: Patients post hematopoietic stem cell transplant (HSCT) are highly susceptible to infection (CDI). Exposure to antibiotic treatment, chemotherapeutic disruption to bacterial microbiome, immunosuppressive therapy, and prolonged hospitalizations synergistically contribute to the risk of CDI and its recurrence. The purpose of this study is to assess if the adjunctive administration of bezlotoxumab decreases the rate of recurrent CDI in patients post-HSCT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!